Reference
Yamamoto H, et al. Therapeutic Potential of Afatinib for Cancers with ERBB2 (HER2) Transmembrane Domain Mutations G660D and V659E. Oncologist 23: 150-154, No. 2, Feb 2018. Available from: URL: http://doi.org/10.1634/theoncologist.2017-0345 - Japan
Rights and permissions
About this article
Cite this article
Afatinib. Reactions Weekly 1694, 20 (2018). https://doi.org/10.1007/s40278-018-43422-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-018-43422-x